Base de dados : MEDLINE
Pesquisa : D03.383.606.515.200 [Categoria DeCS]
Referências encontradas : 1224 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 123 ir para página                         

  1 / 1224 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29262451
[Au] Autor:Chen XQ; Ma Q; Zhou LY; Ma HA; Wu JY; Zhao JJ; Yan DN
[Ad] Endereço:Department of Otorhinolaryngology, Affiliated Hospital of Nanjing University of TCM, Nanjing 210029, China.
[Ti] Título:[Experimental study on the effect of Yiqi Wenyang Decoction on nasal mucosa infiltration of NK cells in mice with allergic rhinitis].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;52(12):921-926, 2017 Dec 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To observe the effect of Yiqi Wenyang Decoction on the infiltration and activation of NK cells in nasal mucosa of mouse model with allergic rhinitis (AR), and to explore the potential mechanism for effective intervention of AR with Yiqi Wenyang Decoction. Fourty-eight mice were randomly divided into blank group, model group, low, medium and high dose of Yiqi Wenyang Decoction group and Cetirizine group, with 8 rats in each group. After modeling of AR, the model group was filled with 0.9% sodium chloride solution. Yiqi Wenyang Decoction groups of each dose were given different concentrations of Yiqi Wenyang Decoction water extract, while the Cetirizine group was given aqueous solution of Cetirizine. The behavior, morphological changes of nasal mucosa and infiltration of NK cells in nasal mucosa were observed. The levels of IL-4 and INF-γ in nasal lavage fluid were measured. Besides, the drug safety was observed by acute toxicity test. In the respect of behavioral scoring, middle and high dose of Yiqi Wenyang Decoction group were superior to the model group (number of sneezing: value was 7.189, 8.748, respectively; number of scratching nose: value was 12.074, 14.560, respectively; all <0.05). In middle and high dose of Yiqi Wenyang Decoction group, the infiltration of NK cells and nasal lavage fluid IL-4 levels were lower than those in model group (IOD: value was 10.073, 12.322, respectively; IOD/Area: value was 10.954, 14.073, respectively; IL-4: value was 4.705, 6.801, respectively; all <0.05). There was no significant difference in nasal lavage fluid of INF-γ among each group ( =1.166, >0.05). In acute toxicity test, no obvious poisoning symptoms and death occurred in mice. Yiqi Wenyang Decoction can control the nasal symptom, reduce the local NK cell infiltration of nasal mucosa and inhibit the expression of the 2-type cytokines released by NK cells, which may be related with the potential mechanism of effective intervention of AR with Yiqi Wenyang Decoction.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/uso terapêutico
Células Matadoras Naturais/efeitos dos fármacos
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antialérgicos/efeitos adversos
Antialérgicos/uso terapêutico
Cetirizina/efeitos adversos
Cetirizina/uso terapêutico
Modelos Animais de Doenças
Medicamentos de Ervas Chinesas/efeitos adversos
Interferon gama/análise
Interleucina-4/análise
Camundongos
Líquido da Lavagem Nasal/química
Mucosa Nasal/citologia
Mucosa Nasal/imunologia
Distribuição Aleatória
Rinite Alérgica/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Drugs, Chinese Herbal); 207137-56-2 (Interleukin-4); 82115-62-6 (Interferon-gamma); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2017.12.009


  2 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779432
[Au] Autor:Sharma VK; Gupta V; Pathak M; Ramam M
[Ad] Endereço:a Department of Dermatology and Venereology , All India Institute of Medical Sciences , New Delhi , India.
[Ti] Título:An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose.
[So] Source:J Dermatolog Treat;28(6):539-543, 2017 Sep.
[Is] ISSN:1471-1753
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The EAACI/GA LEN/EDF/WAO recommendation of increasing antihistamines' dose up to four times in urticaria not adequately controlled with the standard dose is largely based on expert opinion. The objective of this study is to test the current urticaria guidelines of up-dosing antihistamines as second-line treatment. METHODS: This was an open-label study conducted prospectively on 113 patients with chronic spontaneous urticaria. All patients were treated with sequentially increasing doses of levocetrizine (5 mg, 10 mg, 15 mg and 20 mg/day) every week till the patients became completely asymptomatic or dose of 20 mg/day reached. Urticaria Activity Score (UAS)-7, urticaria-related quality-of-life (CU-Q2oL) and patients' global assessment were used to assess treatment response. RESULTS: Twenty-one (18.58%) patients became asymptomatic with levocetirizine 5 mg/day, while 50 required higher doses of levocetirizine for complete control: 29/92 (31.52%), 6/63 (9.52%) and 15/57 (26.31%) with 10 mg, 15 mg and 20 mg/day, respectively. The percentage of patients experiencing >75% improvement increased with increasing doses of levocetirizine: 26.54%, 53.98%, 60.17% and 69.91% with 5 mg, 10 mg, 15 mg and 20 mg/day, respectively. Sequential up-dosing of levocetirizine produced a progressive improvement in both urticaria control (UAS-7) and quality-of-life (CU-Q2oL) without significantly increasing somnolence. CONCLUSIONS: Our results support the current recommendations of increasing antihistamines up to four times the standard dose in patients who fail the first-line treatment.
[Mh] Termos MeSH primário: Cetirizina/uso terapêutico
Antagonistas dos Receptores Histamínicos H1 não Sedativos/uso terapêutico
Urticária/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Cetirizina/efeitos adversos
Doença Crônica
Distúrbios do Sono por Sonolência Excessiva/etiologia
Relação Dose-Resposta a Droga
Feminino
Antagonistas dos Receptores Histamínicos H1 não Sedativos/efeitos adversos
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Qualidade de Vida
Índice de Gravidade de Doença
Resultado do Tratamento
Urticária/patologia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H1 Antagonists, Non-Sedating); 6U5EA9RT2O (levocetirizine); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180110
[Lr] Data última revisão:
180110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1080/09546634.2016.1246705


  3 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686675
[Au] Autor:Landi D; Albanese M; Buttari F; Monteleone F; Boffa L; Rossi S; Motta C; Puma E; Centonze D
[Ad] Endereço:Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
[Ti] Título:Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
[So] Source:PLoS One;12(7):e0165415, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Flu-like syndrome (FLS) is a common adverse event experienced by patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFNß). FLS can lead to poor treatment adherence and early IFNß discontinuation. The involvement of interleukin-6 (IL-6) in the occurrence of FLS has been suggested. We hypothesized that cetirizine, a second-generation histamine H1 receptor antagonist able to reduce the levels of IL-6, might improve IFNß-induced FLS. METHODS: We conducted a pilot, cross-over, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine 10 mg added after each IFNß injection to the standard of care for FLS (acetaminophen or nonsteroidal anti-inflammatory drugs) on FLS in patients with RRMS treated with IFNß. Patients were randomized to two treatment sequences: 1) 4-week treatment with placebo added to the standard treatment for FLS, followed by 4-week treatment with cetirizine added to the standard of care, and 2) first addition of cetirizine, then of placebo. The primary efficacy endpoint was the mean change of FLS severity [11-point visual analog scale (VAS)] after 4 weeks of treatment within each sequence. RESULTS: Forty-five patients (71.1% female, mean age 39.1 years, mean time from RRMS diagnosis 5.8 years) were randomized to treatment sequences 1 and 2. The differences between cetirizine and placebo in the intensity of FLS were not statistically significant: total mean VAS scores at 4 hours from IFNß injection were 3.57 and 3.42 for cetirizine and placebo, respectively (difference -0.15; 95% confidence interval: from -0.74 to 0.44; p = 0.6029). The two treatments were similar also with regard to other efficacy measures considered and to the safety/tolerability profile. CONCLUSIONS: The addition of cetirizine to the standard of care for IFNß-induced FLS in patients with RRMS does not seem to provide significant benefits compared with placebo. Further effort is required to understand the mechanisms underlying IFNß-induced FLS. TRIAL REGISTRATION: EudraCT 2013-001055-12.
[Mh] Termos MeSH primário: Cetirizina/administração & dosagem
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/tratamento farmacológico
Influenza Humana/tratamento farmacológico
Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Análise de Variância
Anti-Inflamatórios não Esteroides/efeitos adversos
Cetirizina/efeitos adversos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia
Feminino
Seres Humanos
Influenza Humana/induzido quimicamente
Influenza Humana/patologia
Interferon beta/efeitos adversos
Interleucina-6/metabolismo
Masculino
Meia-Idade
Esclerose Múltipla Recidivante-Remitente/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (IL6 protein, human); 0 (Interleukin-6); 77238-31-4 (Interferon-beta); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0165415


  4 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28273617
[Au] Autor:Teixeira M; Almeida Â; Calisto V; Esteves VI; Schneider RJ; Wrona FJ; Soares AM; Figueira E; Freitas R
[Ad] Endereço:Department of Chemistry & CESAM, University of Aveiro, 3810-193 Aveiro, Portugal.
[Ti] Título:Toxic effects of the antihistamine cetirizine in mussel Mytilus galloprovincialis.
[So] Source:Water Res;114:316-326, 2017 May 01.
[Is] ISSN:1879-2448
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Recent studies have become increasingly focused on the assessment of pharmaceuticals occurrence in aquatic ecosystems, however the potential toxicity to non-target organisms is still largely unknown. The antihistamine cetirizine is a commonly used pharmaceutical, already detected in surface waters of marine aquatic systems worldwide. In the present study Mytilus galloprovincialis mussels were exposed to a range of cetirizine concentrations (0.3, 3.0, 6.0 and 12.0 µg/L), resembling moderate to highly contaminated areas, over 28 days. The responses of different biochemical markers were evaluated in mussels whole soft tissue, and included energy-related parameters (glycogen content, GLY; protein content, PROT; electron transport system activity, ETS), and oxidative stress markers (superoxide dismutase activity, SOD; catalase activity, CAT; glutathione S-transferases activity, GSTs; lipid peroxidation levels, LPO; reduced (GSH) and oxidized (GSSG) glutathione content). The results obtained demonstrated that with the increase of exposure concentrations mussels tended to increase their energy reserves and maintain their metabolic potential, which was significantly higher only at the highest concentration. Our findings clearly revealed that cetirizine inhibited the activity of GSTs and although induced the activity of antioxidant enzymes (SOD and CAT) mussels were not able to prevent cellular damages observed through the increase of LPO associated to the increase of exposure concentrations. Thus, this study confirmed that cetirizine induces toxic effects in Mytilus galloprovincialis, which, considering their trophic relevance, wide use as bioindicator and wide spatial distribution of this species, can result in ecological and economic negative impacts at a large scale.
[Mh] Termos MeSH primário: Cetirizina
Mytilus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Biomarcadores/metabolismo
Antagonistas dos Receptores Histamínicos
Peroxidação de Lipídeos/efeitos dos fármacos
Poluentes Químicos da Água/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Histamine Antagonists); 0 (Water Pollutants, Chemical); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170505
[Lr] Data última revisão:
170505
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170309
[St] Status:MEDLINE


  5 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28233071
[Au] Autor:Ebid AA; Ibrahim AR; Omar MT; El Baky AM
[Ad] Endereço:Department of Surgery, Faculty of Physical Therapy, Cairo University, Giza, Egypt. anwar.ebid@cu.edu.eg.
[Ti] Título:Long-term effects of pulsed high-intensity laser therapy in the treatment of post-burn pruritus: a double-blind, placebo-controlled, randomized study.
[So] Source:Lasers Med Sci;32(3):693-701, 2017 Apr.
[Is] ISSN:1435-604X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We assessed the long-term effects of pulsed high-intensity laser therapy (HILT) in post-burn pruritus treatment. A total of 49 adult burn patients with mean age of 31.53 ± 10.14 years participated, with 24 patients randomly assigned to the active laser group (ALG) and 25 in the placebo laser group (PLG). The ALG received HILT three times per week for 6 weeks, while the PLG received placebo HILT. Both groups received 10-mg cetirizine tablets twice daily and 10 mg at bedtime. All patients were advised to massage their burn scars with coconut oil for 5 min four times daily. The outcomes measured were the itch severity scale (ISS), impairment of pruritus-related quality of life (QoL), pain level by the visual analog scale (VAS), hand grip strength by handheld dynamometer, and daily cetirizine intake. Repeated-measures ANOVA was used to compare the baseline and post-treatment measurements and after 12 weeks of follow-up. Statistical significance was set at P < 0.05. ISS decreased significantly in the ALG after 6 weeks of treatment and after 12 weeks of follow-up compared with the PLG. The QoL results showed a significant improvement in the ALG compared with the PLG, which continued after 12 weeks. VAS results significantly decrease, hand grip strength significantly improved, and cetirizine intake significantly decreased post-treatment in the ALG relative to the PLG. HILT combined with cetirizine seems more effective in patients with post-burn pruritus than a placebo laser procedure with cetirizine.
[Mh] Termos MeSH primário: Queimaduras/complicações
Terapia a Laser/métodos
Prurido/etiologia
Prurido/radioterapia
[Mh] Termos MeSH secundário: Adulto
Cetirizina/uso terapêutico
Método Duplo-Cego
Feminino
Força da Mão
Seres Humanos
Masculino
Meia-Idade
Medição da Dor
Placebos
Qualidade de Vida
Fatores de Tempo
Resultado do Tratamento
Escala Visual Analógica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Placebos); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170225
[St] Status:MEDLINE
[do] DOI:10.1007/s10103-017-2172-3


  6 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28231047
[Au] Autor:Amelian A; Szekalska M; Ciosek P; Basa A; Winnicka K
[Ti] Título:Original research paper. Characterization and taste masking evaluation of microparticles with cetirizine dihydrochloride and methacrylate-based copolymer obtained by spray drying.
[So] Source:Acta Pharm;67(1):113-124, 2017 Mar 01.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:Taste of a pharmaceutical formulation is an important parameter for the effectiveness of pharmacotherapy. Cetirizine dihydrochloride (CET) is a second-generation antihistamine that is commonly administered in allergy treatment. CET is characterized by extremely bitter taste and it is a great challenge to successfully mask its taste; therefore the goal of this work was to formulate and characterize the microparticles obtained by the spray drying method with CET and poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate 1:2:1 copolymer (Eudragit E PO) as a barrier coating. Assessment of taste masking by the electronic tongue has revealed that designed formulations created an effective taste masking barrier. Taste masking effect was also confirmed by the in vivo model and the in vitro release profile of CET. Obtained data have shown that microparticles with a drug/polymer ratio (0.5:1) are promising CET carriers with efficient taste masking potential and might be further used in designing orodispersible dosage forms with CET.
[Mh] Termos MeSH primário: Cetirizina/administração & dosagem
Excipientes/administração & dosagem
Antagonistas dos Receptores Histamínicos H1 não Sedativos/administração & dosagem
Mascaramento Perceptivo
Ácidos Polimetacrílicos/administração & dosagem
Percepção Gustatória/efeitos dos fármacos
Paladar/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Oral
Aerossóis
Cetirizina/química
Dessecação
Composição de Medicamentos
Nariz Eletrônico
Excipientes/química
Antagonistas dos Receptores Histamínicos H1 não Sedativos/química
Seres Humanos
Cinética
Tamanho da Partícula
Ácidos Polimetacrílicos/química
Limiar Sensorial
Solubilidade
Tecnologia Farmacêutica/instrumentação
Tecnologia Farmacêutica/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Eudragit E PO); 0 (Excipients); 0 (Histamine H1 Antagonists, Non-Sedating); 0 (Polymethacrylic Acids); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170309
[Lr] Data última revisão:
170309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170224
[St] Status:MEDLINE


  7 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28193468
[Au] Autor:Gritti F; Sehajpal J; Fairchild J
[Ad] Endereço:Waters Corporation, 34 Mapple Street, Milford, MA 01757, USA. Electronic address: Fabrice_Gritti@waters.com.
[Ti] Título:Using the fundamentals of adsorption to understand peak distortion due to strong solvent effect in hydrophilic interaction chromatography.
[So] Source:J Chromatogr A;1489:95-106, 2017 Mar 17.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The peak distortion observed in hydrophilic interaction chromatography (HILIC) may be caused by the sample diluent to mobile phase mismatch. The United States Pharmacopeia (USP) method for organic impurities in cetirizine HCl tablets calls for such a mismatch, having a higher concentration of strong solvent in the sample diluent than in the mobile phase. A significant peak deformation is reported for cetirizine (a second-generation antihistamine) when it is purified on a Ethylene Bridged Hybrid (BEH) HILIC column (4.6mm×100mm, 2.5µm particles) using an acetonitrile-water eluent mixture and a sample diluent containing 7% and 9% water (in volume), respectively. The mechanism and physical origin of such peak distortion are related to (1) the diluent-to-eluent excess of water that propagates along the column at a velocity similar to that of the analyte, (2) the significant drop of the Henry's constant of the analyte upon increasing water concentration in the eluent, (3) the sample volume injected, and (4) to the pre-column sample dilution factor that depends on the characteristics of the LC instrument used. This proposed mechanism is validated from the calculation of the concentration profiles of cetirizine and water by using the equilibrium-dispersive (ED) model of chromatography. The observed distortion of cetirizine peaks is successfully predicted from the measurement of (1) the excess adsorption isotherm of water from acetonitrile onto the BEH HILIC adsorbent, (2) the retention factor of cetirizine as a function of the volume fraction (7, 8, and 9%) of water in the mobile phase, and (3) of the pre-column sample dispersion related to the instrument used (HPLC or UHPLC). The results of the calculations enables the user to anticipate the impacts of the diluent-to-eluent mismatch in water content, the injection volume, the analyte retention under infinite dilution, and of the pre-column sample dispersion on the amplitude of peak distortion in HILIC. Appropriate and permitted alterations of the USP method are then suggested based on a sound physico-chemical approach.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão
Solventes/química
[Mh] Termos MeSH secundário: Acetonitrilos/química
Adsorção
Cetirizina/isolamento & purificação
Antagonistas dos Receptores Histamínicos H1 não Sedativos/isolamento & purificação
Interações Hidrofóbicas e Hidrofílicas
Modelos Químicos
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetonitriles); 0 (Histamine H1 Antagonists, Non-Sedating); 0 (Solvents); 059QF0KO0R (Water); YO7261ME24 (Cetirizine); Z072SB282N (acetonitrile)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170215
[St] Status:MEDLINE


  8 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28070872
[Au] Autor:Snidvongs K; Seresirikachorn K; Khattiyawittayakun L; Chitsuthipakorn W
[Ad] Endereço:Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand. drkornkiat@yahoo.com.
[Ti] Título:Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.
[So] Source:Drugs;77(2):175-186, 2017 Feb.
[Is] ISSN:1179-1950
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: As a substrate of P-glycoprotein, levocetirizine should not cause sedative effects. However, while cetirizine, a mixture of levocetirizine and dextrocetirizine, can slightly penetrate the blood brain barrier, the sedative effects of levocetirizine are still under study. OBJECTIVES: The aim of this study was to investigate the sedative effects of levocetirizine. METHODS: An electronic literature search was performed using Medline and EMBASE from January 01, 2001 through August 6, 2015. Randomized controlled trials (RCTs) comparing levocetirizine with other antihistamines or placebo for patients with allergy and healthy subjects were selected. Primary outcome was risk ratio between levocetirizine and comparators. Secondary outcome was change in psychomotor speed. Data were pooled for meta-analysis using a fixed-effect model. RESULTS: Forty-eight studies of 18,014 patients met the inclusion criteria. When compared to placebo, levocetirizine produced modest sedative effects (RR: 1.67; 95% CI 1.17, 2.38). However, when compared to other second-generation antihistamines, sedative effects of levocetirizine did not differ (RR: 1.23; 95% CI 0.96, 1.58). In subgroup analysis, there was no difference between the sedative effects of levocetirizine and fexofenadine (RR: 1.7; 95% CI 0.59, 4.88), desloratadine (RR: 1.58; 95% CI 0.9, 2.77), loratadine (RR: 1.56; 95% CI 0.28, 8.56), bilastine (RR: 1.17; 95% CI 0.48, 2.84), olopatadine (RR: 1.09; 95% CI 0.81, 1.47), azelastine (RR: 0.19; 95% CI 0.01, 3.68) and rupatadine (RR: 1.47; 95% CI 0.14, 15.72). When compared to first-generation antihistamines, levocetirizine had less sedative effects and less change of reaction time (mean difference: -250.76 s; 95% CI -338.53, -162.98). CONCLUSION: Levocetirizine has modest sedative effects with a risk ratio of 1.67 when compared with placebo. The sedative effects observed for levocetirizine are not different from other second-generation antihistamines.
[Mh] Termos MeSH primário: Cetirizina/uso terapêutico
Hipnóticos e Sedativos/uso terapêutico
Urticária/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 6U5EA9RT2O (levocetirizine); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170111
[St] Status:MEDLINE
[do] DOI:10.1007/s40265-016-0682-0


  9 / 1224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27758758
[Au] Autor:Munoz-Cano R; Ainsua-Enrich E; Torres-Atencio I; Martin M; Sánchez-Lopez J; Bartra J; Picado C; Mullol J; Valero A
[Ad] Endereço:Unitat d'Al·lèrgia, Servei de Pneumologia i Al·lèrgia Respiratòria, Hospital Clínic and Universitat de Barcelona, Barcelona, Catalonia, Spain.
[Ti] Título:Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study).
[So] Source:J Investig Allergol Clin Immunol;27(3):161-168, 2017.
[Is] ISSN:1018-9068
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVE: Platelet-activating factor (PAF) is a lipid mediator involved in the pathophysiology of several allergic diseases, for example, in the amplification of mast cell (MC) activation in anaphylaxis. Rupatadine is an antihistamine with a demonstrated anti-PAF effect, although its capacity to inhibit PAF-induced MC degranulation has not been fully evaluated. Objectives: To compare the ability of rupatadine to inhibit PAF-induced MC degranulation with that of desloratadine and levocetirizine and to confirm the dual anti-H1 and anti-PAF activity of rupatadine. METHODS: The human MC line LAD2 and primary MCs (human lung tissue MCs [hLMCs]) were used. MC mediator release was evaluated using the b-hexosaminidase and histamine release assay. The effects of rupatadine (H1 antagonist + PAF receptor antagonist), desloratadine, and levocetirizine (H1 antagonists) on LAD2 and hLMCs were compared. The PAF receptor antagonists WEB2086, BN52021, and CV6209 were also tested. PAF receptor protein expression was evaluated in both LAD2 and hLMCs. RESULTS: CV6209 and rupatadine inhibited PAF-induced MC degranulation in both LAD2 and hLMCs. In LAD2, rupatadine (5 and 10 µM) and levocetirizine (5 µM), but not desloratadine, inhibited PAF-induced b-hexosaminidase release. Rupatadine (1-10 µM), levocetirizine (1-10 µM), and desloratadine (10 µM) inhibited PAF-induced histamine release. Rupatadine at 10 µM had an inhibitory effect on hLMC degranulation, but levocetirizine and desloratadine did not. CONCLUSIONS: This study shows that rupatadine and, to a lesser extent, levocetirizine, but not desloratadine, inhibit PAF-induced degranulation in both LAD2 and hLMCs. These findings support the dual antihistamine and anti-PAF effect of rupatadine in allergic disorders.
[Mh] Termos MeSH primário: Degranulação Celular/efeitos dos fármacos
Cetirizina/farmacologia
Ciproeptadina/análogos & derivados
Antagonistas dos Receptores Histamínicos H1 não Sedativos/farmacologia
Loratadina/análogos & derivados
Mastócitos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Azepinas/farmacologia
Linhagem Celular
Ciproeptadina/farmacologia
Fibrinolíticos/farmacologia
Ginkgolídeos/farmacologia
Antagonistas dos Receptores Histamínicos H1/farmacologia
Seres Humanos
Lactonas/farmacologia
Loratadina/farmacologia
Fator de Ativação de Plaquetas/farmacologia
Inibidores da Agregação de Plaquetas/farmacologia
Glicoproteínas da Membrana de Plaquetas/antagonistas & inibidores
Compostos de Piridínio/farmacologia
Receptores Acoplados a Proteínas-G/antagonistas & inibidores
Triazóis/farmacologia
beta-N-Acetil-Hexosaminidases/efeitos dos fármacos
beta-N-Acetil-Hexosaminidases/secreção
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Azepines); 0 (Fibrinolytic Agents); 0 (Ginkgolides); 0 (Histamine H1 Antagonists); 0 (Histamine H1 Antagonists, Non-Sedating); 0 (Lactones); 0 (Platelet Activating Factor); 0 (Platelet Aggregation Inhibitors); 0 (Platelet Membrane Glycoproteins); 0 (Pyridinium Compounds); 0 (Receptors, G-Protein-Coupled); 0 (Triazoles); 0 (platelet activating factor receptor); 100488-87-7 (CV 6209); 105219-56-5 (WEB 2086); 2AE8M83G3E (rupatadine); 2YHB6175DO (Cyproheptadine); 6U5EA9RT2O (levocetirizine); 7AJO3BO7QN (Loratadine); DF149B9460 (ginkgolide B); EC 3.2.1.52 (beta-N-Acetylhexosaminidases); FVF865388R (desloratadine); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161021
[St] Status:MEDLINE
[do] DOI:10.18176/jiaci.0117


  10 / 1224 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27504742
[Au] Autor:Rossi A; Miraglia E; Fortuna MC; Calvieri S; Giustini S
[Ad] Endereço:Department of Dermatology and Venereology, "Sapienza" University of Rome, Rome, Italy.
[Ti] Título:Topical cetirizine and oral vitamin D: a valid treatment for hypotrichosis caused by ectodermal dysplasia.
[So] Source:J Eur Acad Dermatol Venereol;31(2):367-370, 2017 Feb.
[Is] ISSN:1468-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ectodermal dysplasia is a clinically and genetically heterogeneous group of inherited disorders characterized by abnormal development of two or more of the following ectodermal-derived structures: hair, teeth, nails and sweat glands. The hair is the most frequently affected structure. Hair shaft abnormalities are of great concern to these patients, but no effective treatments are available. METHODS: We describe three girls with congenital hypotrichosis (9, 5 and 6 years old) caused by ectodermal dysplasia treated with topical cetirizine solution (2 mL. once daily) and oral vitamin D supplementation (1000 IU daily). RESULTS: After 6 months of treatment, the density of hair on the scalp increased in all patients. The vellus hair was replaced by terminal hair. Hair regrowth was evaluated both from the clinical and trichoscopic point of view. CONCLUSION: We propose a combination of topical cetirizine and oral vitamin D as a rational treatment of choice in congenital hypotrichosis caused by ectodermal dysplasia.
[Mh] Termos MeSH primário: Cetirizina/administração & dosagem
Displasia Ectodérmica/tratamento farmacológico
Hipotricose/tratamento farmacológico
Vitamina D/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Administração Tópica
Criança
Displasia Ectodérmica/complicações
Feminino
Seres Humanos
Hipotricose/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
1406-16-2 (Vitamin D); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160810
[St] Status:MEDLINE
[do] DOI:10.1111/jdv.13864



página 1 de 123 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde